GM101 injection for advanced Parkinson's disease
Part of Brain & nervous system clinical trials.
This trial tests an investigational gene therapy injection called GM101 for people with advanced Parkinson's disease whose symptoms are not well controlled by standard medications. The study will see if this treatment can help improve movement and quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 40 and 70 years old.
- You have had Parkinson's disease for at least 5 years.
- Your Parkinson's symptoms are severe (Hoehn-Yahr stage 4-5) when you are off medication.
- Current medications do not control your symptoms well, or you have bad side effects from them.
- You are willing to undergo a surgical procedure and imaging tests like CT or MRI.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a gene therapy product called VGN-R08b for people with Parkinson's disease who have a specific genetic change (GBA1 mutation). The goal is to help improve movement and daily function.
This trial tests a gene therapy for people with advanced Parkinson's disease (at least 10 years since diagnosis). It uses a special infusion to deliver treatment directly into the brain. The goal is to see if it can improve motor symptoms.
This study tests a new gene therapy called LY-N001, which is injected directly into the brain. It is for people with moderate to advanced Parkinson's disease who have a specific genetic change in the GBA1 gene. The goal is to see if this treatment is safe and can help improve symptoms.
This trial tests an injection called XS411CN for people with Parkinson's disease whose current medications are not working as well as before. The goal is to see if it is safe and tolerable.
This trial tests a new gene therapy called BBM-P002 for Parkinson's disease. It aims to see if the treatment is safe and tolerable, and may help people with moderate to advanced Parkinson's who have had the condition for at least 5 years.
This trial tests an investigational drug called GT-02287 in people with early-stage Parkinson's disease (diagnosed within the last 7 years). The goal is to see if it is safe and how the body processes it, with a special focus on people with certain genetic changes (GBA1 mutations) that may be linked to Parkinson's.
Hear when a new Parkinson's Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.